NEA Management Company, LLC reported 26 positions worth $1.59B for the quarter ended Jun 30, 2026, down 9.7% on the prior quarter. It opened 1 new position, added to 0, trimmed 2 and exited 1. Its largest holding is Trevi Therapeutics, Inc. at 15.5% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| KPTI Karyopharm Therapeutics Inc. | +576.8K | – | $5.64M | 0.355% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| KPTI Karyopharm Therapeutics Inc. | +576.8K | $5.64M | 0.355% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| ACLX GILEAD SCIENCES INC- CVR CONTINGENT VALUE RIGHT | -3.05M | $349.66M | 19.88% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | TRVI Trevi Therapeutics, Inc. | Healthcare | 13.22M | $246.59M | 15.53% | 0 | 0.0% | Unchanged | 8.44% |
| 2 | MBX MBX Biosciences, Inc. | Healthcare | 3.61M | $199.52M | 12.56% | 0 | 0.0% | Unchanged | 7.54% |
| 3 | GLUE Monte Rosa Therapeutics, Inc. | Healthcare | 7.69M | $186.15M | 11.72% | 0 | 0.0% | Unchanged | 7.58% |
| 4 | CELC Celcuity Inc. | Healthcare | 1.71M | $178.96M | 11.27% | -575.0K | -25.2% | Reduced | 3.12% |
| 5 | SGP SpyGlass Pharma, Inc. | Healthcare | 7.39M | $164.55M | 10.36% | 0 | 0.0% | Unchanged | 22.1% |
| 6 | SVRA Savara Inc | Healthcare | 24.47M | $150.74M | 9.49% | 0 | 0.0% | Unchanged | 9.65% |
| 7 | ZBIO Zenas BioPharma, Inc. | Healthcare | 4.02M | $102.11M | 6.43% | 0 | 0.0% | Unchanged | 6.35% |
| 8 | COUR Coursera, Inc. | Technology | 12.87M | $72.57M | 4.57% | 0 | 0.0% | Unchanged | 4.69% |
| 9 | AUPH Aurinia Pharmaceuticals Inc. | Healthcare | 3.97M | $67.37M | 4.24% | 0 | 0.0% | Unchanged | 2.99% |
| 10 | CRSP CRISPR Therapeutics AG | Healthcare | 1.06M | $57.73M | 3.64% | 0 | 0.0% | Unchanged | 1.1% |
| 11 | ORIC Oric Pharmaceuticals, Inc. | Healthcare | 4.12M | $44.60M | 2.81% | 0 | 0.0% | Unchanged | 3.81% |
| 12 | PHAT Phathom Pharmaceuticals, Inc. | Healthcare | 1.96M | $21.27M | 1.34% | 0 | 0.0% | Unchanged | 2.34% |
| 13 | KRRO Korro Bio, Inc. | Healthcare | 1.30M | $17.11M | 1.08% | 0 | 0.0% | Unchanged | 7.37% |
| 14 | XFOR X4 Pharmaceuticals, Inc | Healthcare | 3.23M | $15.10M | 0.951% | 0 | 0.0% | Unchanged | 2.56% |
| 15 | CSBR Champions Oncology, Inc. | Healthcare | 1.71M | $10.56M | 0.665% | 0 | 0.0% | Unchanged | 12.34% |
Tip. Select a row to see that position’s full history at NEA Management Company.
As of its Q2 2026 13F filing, NEA Management Company, LLC’s five largest positions were Trevi Therapeutics, Inc. (TRVI) at 15.5%, MBX Biosciences, Inc. (MBX) at 12.6%, Monte Rosa Therapeutics, Inc. (GLUE) at 11.7%, Celcuity Inc. (CELC) at 11.3%, SpyGlass Pharma, Inc. (SGP) at 10.4% of the reported portfolio.
NEA Management Company, LLC reported a 13F portfolio worth $1.59B across 26 positions for Q2 2026. That is down 9.7% from the previous quarter.
Its largest purchases by value were Karyopharm Therapeutics Inc. ($5.64M). It opened 1 new positions.
Its largest sales by value were GILEAD SCIENCES INC- CVR CONTINGENT VALUE RIGHT ($349.66M), Celcuity Inc. ($60.16M), CVRx, Inc. ($368.25K). It exited 1 positions entirely.
From the Form 13F-HR reports NEA Management Company, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.